Titre : Cellules HepG2

Cellules HepG2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Intestinal Failure
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cellules HepG2 : Questions médicales les plus fréquentes", "headline": "Cellules HepG2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cellules HepG2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-11", "dateModified": "2025-05-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cellules HepG2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hépatocytes", "url": "https://questionsmedicales.fr/mesh/D022781", "about": { "@type": "MedicalCondition", "name": "Hépatocytes", "code": { "@type": "MedicalCode", "code": "D022781", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.436.348" } } }, "about": { "@type": "MedicalCondition", "name": "Cellules HepG2", "alternateName": "Hep G2 Cells", "code": { "@type": "MedicalCode", "code": "D056945", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wilson de Melo Cruvinel", "url": "https://questionsmedicales.fr/author/Wilson%20de%20Melo%20Cruvinel", "affiliation": { "@type": "Organization", "name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com." } }, { "@type": "Person", "name": "Paulo Luiz Carvalho Francescantonio", "url": "https://questionsmedicales.fr/author/Paulo%20Luiz%20Carvalho%20Francescantonio", "affiliation": { "@type": "Organization", "name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil." } }, { "@type": "Person", "name": "Alessandra Dellavance", "url": "https://questionsmedicales.fr/author/Alessandra%20Dellavance", "affiliation": { "@type": "Organization", "name": "Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil." } }, { "@type": "Person", "name": "Luis Eduardo Coelho Andrade", "url": "https://questionsmedicales.fr/author/Luis%20Eduardo%20Coelho%20Andrade", "affiliation": { "@type": "Organization", "name": "Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br." } }, { "@type": "Person", "name": "Antônio Carlos Ximenes", "url": "https://questionsmedicales.fr/author/Ant%C3%B4nio%20Carlos%20Ximenes", "affiliation": { "@type": "Organization", "name": "Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Central venous catheter safety in pediatric patients with intestinal failure.", "datePublished": "2023-08-03", "url": "https://questionsmedicales.fr/article/37537891", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ncp.11047" } }, { "@type": "ScholarlyArticle", "name": "ESPEN guideline on chronic intestinal failure in adults - Update 2023.", "datePublished": "2023-07-29", "url": "https://questionsmedicales.fr/article/37639741", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clnu.2023.07.019" } }, { "@type": "ScholarlyArticle", "name": "Assessment of body composition in pediatric intestinal failure: A comparison study.", "datePublished": "2023-07-17", "url": "https://questionsmedicales.fr/article/37355855", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jpen.2540" } }, { "@type": "ScholarlyArticle", "name": "Development of a core outcome set for pediatric chronic intestinal failure.", "datePublished": "2023-01-08", "url": "https://questionsmedicales.fr/article/36546585", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jpen.2468" } }, { "@type": "ScholarlyArticle", "name": "Characteristics of adult intestinal failure centers: An international multicenter survey.", "datePublished": "2022-10-29", "url": "https://questionsmedicales.fr/article/36309481", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ncp.10926" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Cellules", "item": "https://questionsmedicales.fr/mesh/D002477" }, { "@type": "ListItem", "position": 3, "name": "Cellules épithéliales", "item": "https://questionsmedicales.fr/mesh/D004847" }, { "@type": "ListItem", "position": 4, "name": "Hépatocytes", "item": "https://questionsmedicales.fr/mesh/D022781" }, { "@type": "ListItem", "position": 5, "name": "Cellules HepG2", "item": "https://questionsmedicales.fr/mesh/D056945" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cellules HepG2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cellules HepG2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cellules HepG2", "description": "Comment identifier les cellules HepG2 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les HepG2 ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Intestinal+Failure&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cellules HepG2", "description": "Les cellules HepG2 présentent-elles des symptômes ?\nQuels marqueurs sont associés aux cellules HepG2 ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Intestinal+Failure&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cellules HepG2", "description": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?\nComment les HepG2 contribuent-elles à la recherche préventive ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Intestinal+Failure&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cellules HepG2", "description": "Peut-on utiliser HepG2 pour tester des médicaments ?\nComment les HepG2 aident-elles à développer des traitements ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Intestinal+Failure&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cellules HepG2", "description": "Quelles complications peuvent être étudiées avec HepG2 ?\nLes HepG2 aident-elles à comprendre les complications du foie ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Intestinal+Failure&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cellules HepG2", "description": "Quels facteurs de risque sont étudiés avec HepG2 ?\nComment HepG2 aide à identifier des facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Intestinal+Failure&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les cellules HepG2 en laboratoire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine." } }, { "@type": "Question", "name": "Quelles techniques sont utilisées pour étudier les HepG2 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire." } }, { "@type": "Question", "name": "Les cellules HepG2 présentent-elles des symptômes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro." } }, { "@type": "Question", "name": "Quels marqueurs sont associés aux cellules HepG2 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques." } }, { "@type": "Question", "name": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques." } }, { "@type": "Question", "name": "Comment les HepG2 contribuent-elles à la recherche préventive ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique." } }, { "@type": "Question", "name": "Peut-on utiliser HepG2 pour tester des médicaments ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments." } }, { "@type": "Question", "name": "Comment les HepG2 aident-elles à développer des traitements ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques." } }, { "@type": "Question", "name": "Quelles complications peuvent être étudiées avec HepG2 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées." } }, { "@type": "Question", "name": "Les HepG2 aident-elles à comprendre les complications du foie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques." } }, { "@type": "Question", "name": "Quels facteurs de risque sont étudiés avec HepG2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés." } }, { "@type": "Question", "name": "Comment HepG2 aide à identifier des facteurs de risque ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques." } } ] } ] }

Sources (10000 au total)

ESPEN guideline on chronic intestinal failure in adults - Update 2023.

In 2016, ESPEN published the guideline for Chronic Intestinal Failure (CIF) in adults. An updated version of ESPEN guidelines on CIF due to benign disease in adults was devised in order to incorporate... The grading system of the Scottish Intercollegiate Guidelines Network (SIGN) was used to grade the literature. Recommendations were graded according to the levels of evidence available as A (strong), ... The recommendations of the 2016 guideline were reviewed, particularly focusing on definitions, and new chapters were included to devise recommendations on IF centers, chronic enterocutaneous fistulas,... It is confirmed that CIF management requires complex technologies, multidisciplinary and multiprofessional activity, and expertise to care for the underlying gastrointestinal disease and to provide HP...

Assessment of body composition in pediatric intestinal failure: A comparison study.

The objective of the study was to compare bioelectrical impedance analysis (BIA) and skinfolds with dual energy x-ray absorptiometry (DXA) in the assessment of body composition of children with intest... Children aged 1-18 years with intestinal failure whohave DXA as part of routine clinical monitoring were eligible. BIA measured total body water on the same day as DXA. Skinfold measurements were take... Sixty-eight children with intestinal failure, mean age 8.9 ± 4.2 years, were studied. There was no difference between %FFM and %FM obtained by DXA and BIA (P = 0.26), with a mean bias (95% CI) of -0.6... BIA is an acceptable clinical tool for assessing body composition in pediatric intestinal failure....

Development of a core outcome set for pediatric chronic intestinal failure.

In research on pediatric chronic intestinal failure, heterogeneity in reported definitions and outcomes exists. This leads to a risk of reporting bias and impossibility of evidence synthesis. Also, re... Candidate outcomes were selected from a recent systematic review. A three-round Delphi study among key stakeholders and a consensus meeting with an expert panel were undertaken to achieve consensus on... Seventy-two stakeholders (79%) completed all three rounds of the Delphi process. Ninety-eight outcomes were assessed, and five new outcomes were added after the first round. Ten outcomes were included... This pediatric chronic intestinal failure COS consists of 10 outcomes important for all key stakeholders. Usage of this set in future research should minimize outcome heterogeneity and enhance the val...

Characteristics of adult intestinal failure centers: An international multicenter survey.

Current guidelines recommend that patients with chronic intestinal failure (CIF) should be managed by a multidisciplinary team (MDT). However, the characteristics of real-world IF centers and the pati... This is an international multicenter study of adult IF centers using a survey. The questionnaire survey included questions regarding program and patient characteristics. Thirty-three investigational c... The survey center response rate was 91%. The median number of patients with CIF per center was 128 (range, 30-380). The most common disciplines reported were gastroenterologist (93%), dietitian (90%),... The majority of centers were managing around 100 patients with CIF. Despite the widespread use of the MDT, there are some variances in team characteristics. Gastroenterologists were the most common ph...

High Rate of Venous Thromboembolism in Severe Pediatric Intestinal Failure.

To quantify the rate of venous thromboembolism (VTE) in patients with pediatric intestinal failure and identify associated risk factors.... We performed a retrospective cohort study in pediatric patients (<21 years old) with severe pediatric intestinal failure (≥90 consecutive days of parenteral nutrition) secondary to short bowel syndrom... A total of 263 patients (59.7% male) met the criteria for inclusion. The cumulative incidence of VTE was 28.1%, with a rate of 0.32 VTEs per 1000 catheter-days. On univariate analysis, the number of c... In this retrospective study, 28.1% of patients with severe pediatric intestinal failure developed VTE; the number of catheters and early gestational age were noted to be independent risk factors for V...

Pitfalls of iron supplementation in parenteral nutrition admixtures for children with intestinal failure.

Pediatric patients with intestinal failure are at increased risk for iron deficiency. Supplementation is not routinely included in parenteral nutrition solutions. There is currently limited research r... We review a patient case and the current available literature related to iron in parenteral nutrition.... Five major concerns are identified: peroxidation reactions, incompatibility, hypersensitivity, infection risk, and iron overload.... We propose an argument against the preferential use of iron supplementation within parenteral nutrition in children with intestinal failure when enteral supplementation or intermittent parenteral infu...

Chronic Mucosal Inflammation in Pediatric Intestinal Failure Patients-A Unique Phenomenon.

As intestinal failure (IF) management improves and long-term survival rate increases, its physiological complications have become more apparent. The development of chronic intestinal inflammation rese... This retrospective study was based on the electronic medical records of pediatric patients seen at the Cincinnati Children's Hospital Medical Center between January 2000 and July 2022. Demographic and... During the follow-up period, 23 children were diagnosed with chronic intestinal inflammation. Of these, 12 (52%) were males, with a median age of 4.5 (3-7) years at diagnosis. Nearly one-third of the ... SBS patients are at risk of relatively early onset chronic intestinal inflammation. The absence of an ICV (and adjoin ileum) and prior lengthening procedures emerge as factors associated with the risk...

Nutritional Management of Intestinal Failure due to Short Bowel Syndrome in Children.

The most common cause of intestinal failure (IF) in childhood remains short bowel syndrome (SBS), where bowel mass is significantly reduced due to a congenital atresia or resection and parenteral nutr... A literature search was performed from 1992 to 2022 using Pubmed, MEDLINE and Cochrane Database of Systematic Reviews, and recent guidelines were reviewed. In the absence of evidence, recommendations ... Consensus on the best possible way of feeding children with IF-SBS is lacking and practice varies widely between centres. Feeding should commence as soon as possible following surgery. Oral feeding is... To date, uniform agreement on the optimal type of feed, timing of food introduction and feeding regime used is lacking and great difference in practice remains. There is need for more research to esta...